ARS Pharmaceuticals, Inc.

SPRY

US82835W1080

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2024 am IST			5-day change	1st Jan Change
11.33 ^USD	-0.09%		+8.32%	+106.75%

11/07	Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing	MT
11/07	Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing	MT

ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2500 Value Index

July 01, 2024

Latest news about ARS Pharmaceuticals, Inc.

Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing	12/07	MT
Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing	12/07	MT
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 3000E Value Index	01/07	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Value Index	01/07	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 3000 Value Index	01/07	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2500 Value Index	01/07	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Microcap Value Index	01/07	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Small Cap Comp Value Index	01/07	CI
ARS Pharmaceuticals' Adrenaline Nasal Spray Receives EMA Committee's Positive Opinion	28/06	MT
EU regulator recommends approval for ARS pharma's nasal spray alternative to EpiPen	28/06	RE
ARS Pharmaceuticals, Inc. Announces EURneffy (Adrenaline Nasal Spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (Anaphylaxis)	28/06	CI
Ars Pharmaceuticals Insider Sold Shares Worth $913,917, According to a Recent SEC Filing	14/06	MT
ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp	30/04	CI
Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand	30/04	CI
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	18/04	MT
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	18/04	MT
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing	11/04	MT
ARS Pharmaceuticals Files Response to FDA Complete Response Letter For Neffy	03/04	MT
ARS Pharmaceuticals Submits Response to FDA Letter for Neffy	03/04	DJ
ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)	03/04	CI
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) added to S&P Biotechnology Select Industry Index	18/03	CI
North American Morning Briefing : Stock Futures -2-	06/03	DJ
Leerink Partners Upgrades ARS Pharmaceuticals to Outperform From Market Perform, Raises Price Target to $18 From $6	05/03	MT

Chart ARS Pharmaceuticals, Inc.

Duration

Period

More charts

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ARS Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.33 USD

Average target price

19 USD

Spread / Average Target

+67.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARS PHARMACEUTICALS, INC.	+106.75%	1.1B
MODERNA, INC.	+24.74%	47.96B
IQVIA HOLDINGS INC.	-0.47%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	31.6B
ICON PUBLIC LIMITED COMPANY	+17.96%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.56B
MEDPACE HOLDINGS, INC.	+42.56%	14.14B
BIO-TECHNE CORPORATION	+1.46%	12.58B

Other Biotechnology & Medical Research